{"id":"NCT05463744","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","officialTitle":"A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-08-12","primaryCompletion":"2024-05-07","completion":"2024-05-07","firstPosted":"2022-07-19","resultsPosted":"2025-06-24","lastUpdate":"2025-06-24"},"enrollment":692,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes","Diabetes"],"interventions":[{"type":"DRUG","name":"Insulin Efsitora Alfa","otherNames":["LY3209590 and Basal Insulin-FC"]},{"type":"DRUG","name":"Insulin Degludec","otherNames":[]}],"arms":[{"label":"Insulin Efsitora Alfa","type":"EXPERIMENTAL"},{"label":"Insulin Degludec","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 [Noninferiority Analysis]","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"500 U/mL Insulin Efsitora Alfa","deltaMin":-0.51,"sd":0.0469},{"arm":"100 U/mL Insulin Degludec","deltaMin":-0.56,"sd":0.0463}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":83,"countries":["United States","Argentina","Japan","Poland","Puerto Rico","Slovakia","Taiwan"]},"refs":{"pmids":["39270686"],"seeAlso":["https://trials.lilly.com/en-US/trial/351115"]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":343},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Influenza","Covid-19","Dermatitis contact"]}}